List of Vosevi drug patents
Vosevi is owned by Gilead Sciences Inc.
Vosevi contains Sofosbuvir; Velpatasvir; Voxilaprevir.
Vosevi has a total of 33 drug patents out of which 0 drug patents have expired.
Vosevi was authorised for market use on 18 July, 2017.
Vosevi is available in tablet;oral dosage forms.
Vosevi can be used as treatment of adult patients with chronic hcv infection who have genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an hcv regimen containing an ns5a inhibitor; treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor, treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor; treatment of adult patients with chronic hcv infection who have genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an hcv regimen containing an ns5a inhibitor.
Drug patent challenges can be filed against Vosevi from 2021-07-18.
The generics of Vosevi are possible to be released after 01 December, 2037.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(4 years from now) | |
| US9585906 | GILEAD SCIENCES INC | NA |
Mar, 2028
(4 years from now) | |
| US8735372 | GILEAD SCIENCES INC | NA |
Mar, 2028
(4 years from now) | |
| US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(4 years from now) | |
| US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(4 years from now) | |
| US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(5 years from now) | |
| US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(5 years from now) | |
| US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(5 years from now) | |
| US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(7 years from now) | |
| US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(7 years from now) | |
| US8575135 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(9 years from now) | |
| US9868745 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(9 years from now) | |
| US8940718 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(9 years from now) | |
| US8921341 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(9 years from now) | |
| US9296782 | GILEAD SCIENCES INC | Inhibitors of hepatitis C virus |
Jul, 2034
(11 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8957046 | GILEAD SCIENCES INC | NA |
Mar, 2028
(4 years from now) | |
|
US9085573 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
|
US8580765 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
|
US8334270 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
|
US8735372 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
|
US8889159 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(6 years from now) | |
|
US7964580 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2029
(6 years from now) | |
|
US8633309 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2029
(6 years from now) | |
|
US9284342 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2031
(7 years from now) | |
|
US8618076 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Jun, 2031
(8 years from now) | |
|
US8921341 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(9 years from now) | |
|
US8575135 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(9 years from now) | |
|
US8940718 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(9 years from now) | |
| US11116783 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(10 years from now) | |
|
US11116783 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(11 years from now) | |
| US10912814 | GILEAD SCIENCES INC | Combination formulation of three antiviral compounds |
Jun, 2037
(13 years from now) | |
| US11338007 | GILEAD SCIENCES INC | Combination formulation of three antiviral compounds |
Jun, 2037
(13 years from now) | |
|
US11338007 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of three antiviral compounds |
Dec, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 18, 2022 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient
NCE-1 date: 2021-07-18
Market Authorisation Date: 18 July, 2017
Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor; Treatme...
Dosage: TABLET;ORAL
VOSEVI family patents
106
United States
36
Japan
36
European Union
26
Korea, Republic of
23
China
22
Australia
21
Spain
20
Canada
20
Hong Kong
20
New Zealand
20
Singapore
17
Portugal
16
Israel
15
Poland
15
Slovenia
15
Taiwan
15
Mexico
15
EA
14
Brazil
12
Argentina
11
Chile
9
Denmark
9
Croatia
9
Hungary
9
Uruguay
9
Cyprus
8
Philippines
8
Colombia
7
Peru
7
Lithuania
7
RS
7
South Africa
7
Ecuador
6
ME
6
Ukraine
6
Costa Rica
6
Moldova, Republic of
5
Morocco
5
Malaysia
4
San Marino
4
Russia
3
Germany
2
AP
1
Luxembourg
1
Turkey
1
Netherlands
1
India
1
Norway
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic